42. Initial evaluation of the effectiveness of ramucirumab in advanced gastric Cancer at K Hospital
Main Article Content
Abstract
Ramucirumab is a monoclonal antibody that binds to VEGFR-2 has been proven to be effective in the treatment of many types of cancer such as stomach, lung, and colorectal cancers. This is a retrospective descriptive study of 22 patients with advanced stage of gastric cancer at K Hospital treated with a regimen containing ramucirumab from March 2023 to June 2024. The median age was 60.1 ± 8.8 years old. The majority of patients are in stage 4, accounting for 77.3%. The percentage of patient who use regimen paclitaxel - ramucirumab, irinotecan - ramucirumab, ramucirumab monotherapy was 68.2%, 22.7% and 9.1%, respectively. The mean cycle ramucirumab is 7. Objective response rate (ORR) was 31.8%. Stable disease was observed in 22.7% of patients with a disease control rate of 54.5%. Median progression free survival (PFS) was 3.2 months, whereas median overall survival (OS) was 8.5 months.
Article Details
Keywords
Gastric cancer, ramucirumab
References
2. Ford H E R, Marshall A, Bridgewater J A, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014; 15: 78-86. doi: 10.1016/S1470-2045(13)70549-7.
3. Thuss-Patience P C, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer. 2011; 47:2306-2314. doi: 10.1016/j.ejca.2011.06.002.
4. Spratlin J L, Roger B Cohen, Matthew Eadens, et al. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. J. Clin. Oncol. 2010; 28:780-787. doi: 10.1200/JCO.2009.23.7537.
5. Wilke H, Muro K, Cutsem E V, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15:1224-1235. doi: 10.1016/S1470-2045(14)70420-6.
6. Shitara K, Muro K, Shimada Y, et al. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016; 19:927-938. doi: 10.1007/s10120-015-0559-z.
7. Di Bartolomeo M, Niger M, Tirino G, et al. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. Target. Oncol. 2018; 13: 227-234. doi: 10.1007/s11523-018-0562-5.
8. Fuchs C S, Tomasek J, Yong C J, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2014; 383: 31-39. doi: 10.1016/S0140-6736(13)61719-5.
9. Kawamoto Y, Yuki S, Sawada K, et al. Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603). J. Clin. Oncol. 2021; 39: 217-217. doi: 10.1200/JCO.2021.39.3_suppl.217.
10. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, Phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013; 31. doi: 10.1200/JCO.2012.48.5805.